Skip to main content
Cloudy icon
50º
Join Insider
Trending
Employee charged after child reports sexual assault at NRG Stadium during Texans game
These are the most stolen vehicles in the Houston area, per Pct. 4
Texas investigates claims grocery stores spray produce with pesticides without warning
‘This ends now’: Suspect in Houston METRO bus shooting reprimanded by judge for rolling eyes
No more driving to Houston: Baytown’s new events center will host concerts and sports
Investigation into Humble PD continues as chief remains on unpaid leave; expenses revealed by city
Suspect in bank robbery on UH campus wore fake breasts, hijab during heist, source says
Driver stalled in middle of Katy Freeway, hit and killed by tow truck

Health

FDA has fast-tracked promising drug to treat COVID-19 patients and it is in trial at Houston Methodist

KPRC 2 Staff

File

HOUSTON – The U.S. Food and Drug Administration has fast-tracked a promising drug to treat COVID-19 patients and it is in trial at Houston Methodist Hospital.

The drug is called RLF-100 and is also known as aviptadil. It has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA’s Phase 2/3 trials.

Recommended Videos

According to a press release from the drug maker NeuroRX, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.

The drug has been successful in reducing lung inflammation and so the FDA now says any doctor at any hospital can request this treatment to help severely ill COVID-19 patients.

To learn more about the RLF-100, click here.

Correction:

This story was not up to KPRC 2's journalistic standards. It has since been updated with confirmed information.

Copyright 2020 by KPRC Click2Houston - All rights reserved.

Recommended Videos